• Vaxart, Inc. recently presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, offering updates to investors and industry participants on its oral vaccine programs.

• This forum gave management a high-visibility platform to explain progress on its oral vaccine technology and potential partnering opportunities, which can influence how the company’s prospects are perceived.

• We’ll now examine how Vaxart’s Oppenheimer conference appearance, and any fresh detail on its oral vaccine pipeline, reshapes its investment narrative.

Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Vaxart Investment Narrative Recap

To own Vaxart, you have to believe its oral vaccine platform can translate recent clinical and partnership progress into durable commercial products. The Oppenheimer presentation mainly served as a communications event, so it does not appear to materially change the near term focus on the Phase IIb COVID 19 readouts as the key catalyst, or the ongoing reliance on external funding and partnerships as the central risk.

In that context, the Dynavax license agreement for Vaxart’s oral COVID 19 vaccine looks especially relevant. It brings an upfront US$25 million cash payment, a US$5 million equity stake, and up to US$700 million in potential milestones and royalties, which tie future upside closely to trial outcomes and partner execution, while partially offsetting funding risk highlighted around the Oppenheimer appearance.

Yet in contrast to the promise of the Dynavax deal, investors should also be aware of...

Read the full narrative on Vaxart (it's free!)

Vaxart's narrative projects $40.7 million revenue and $6.5 million earnings by 2028. This implies a 35.0% yearly revenue decline but an earnings improvement of $57.2 million from $-50.7 million today.

Uncover how Vaxart's forecasts yield a $3.33 fair value , a 319% upside to its current price.

Exploring Other Perspectives

The most optimistic analysts were assuming revenue could reach about US$128.2 million by 2029 with earnings of roughly US$20.8 million, so the Oppenheimer update and BARDA funding risks they downplayed may now look very different in light of how dependent that path is on successful Phase IIb COVID 19 data and partner follow through.

Explore 10 other fair value estimates on Vaxart - why the stock might be a potential multi-bagger!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.